AllDocs -> cancers

The Role of Amifostine as a Radioprotectant in the Management of Patients with Squamous Cell Head and Neck Cancer Practice Guideline Report # 5-8 D.I. Hodson, G.P. Browman, K. Thephamongkhol, T. Oliver, L. Zuraw, and members of the Head and Neck Cancer Disease Site Group ORIGINAL GUIDELINE: May 13, 2003 NEW EVIDENCE ADDED TO THE GUIDELINE REPORT: November 18 2003 MOST RECENT LITERATURE SEARCH: March 2004 New evidence found by update searches since the completion of the original guideline is consistent with the original recommendation. SUMMARY Guideline Question For patients with squamous cell head and neck cancer , does amifostine safely and effectively ameliorate important side effects of radiotherapy with acceptable toxicity and no tumour protection? Xerostomia, mucositis, and the anti-tumour effects of amifostine were the main outcomes of interest. Target ...

REPORT BY THE COMPTROLLER AND AUDITOR GENERAL HC 364 Session 2003-2004: 19 March 2004 Tackling cancer in England: saving more lives Page 2 The National Audit Office scrutinises public spending on behalf of Parliament. The Comptroller and Auditor General, Sir John Bourn, is an Officer of the House of Commons. He is the head of the National Audit Office, which employs some 800 staff. He, and the National Audit Office, are totally independent of Government. He certifies the accounts of all Government departments and a wide range of other public sector bodies; and he has statutory authority to report to Parliament on the economy, efficiency and effectiveness with which departments and other bodies have used their resources. Our work saves the taxpayer millions of pounds every year. At least £8 for every £1 spent running the Office. ...

Medical Research Council 21 ST CENTURY HEALTHCARE Improved healthcare and successes in tackling infectious disease during the 20th century have greatly improved life expectancy. Now that more people live longer, ill-health due to degenerative disease, ageing or injury, will place an ever increas- ing burden on the health- care system. Finding new treatments, and eventually cures, for these conditions is therefore a priority. research in focus CANCER What is cancer ? Cancer arises when genetic damage or defects, allow individual cells to escape from their normal growth control mechanisms and divide uncontrollably to create more and more abnormal cancer cells. Proliferating cancer cells increasingly interfere with vital bodily functions, causing illness and eventual death if their multiplication ...

Over a quarter of a mil- lion women will hear the diagnosis of breast cancer every year. As many as 30 percent of these women will expe- rience persistent psy- chosocial distress due to this diagnosis. Breast cancer will kill about forty thousand women each year. Over a quarter of a million women will hear the diagnosis of breast cancer every year, and breast cancer will kill about forty thousand women each year. Naturally, when faced with this news, women will variously experience fear, shock, sadness, disbelief or other feelings of psychosocial distress. Most women, with or without psychosocial support, will cope with psychological problems associated with living with breast can- cer and successfully adjust to and manage their disease and survivorship. A small proportion, however, perhaps as many as 30 percent, will experience episodes ...

PROSTATE Wesley Garrett is a walking testimonial to the value of routine screening for prostate cancer with the prostate-specific antigen (PSA) blood test. When he’s not building oilfield equipment and repairing electric motors, he enjoys fishing, Houston Comets’ games and family outings. Just the Facts Prostate Cancer Your best chance for surviving prostate cancer is detecting it early.When prostate cancer is found early,there is nearly a 100 percent chance for cure. Symptoms There are often no symtoms of prostate cancer in it’s earliest stages.If symptoms are present,they vary from man to man,and may include: • frequent urination • hard time when starting to urinate,or trying to hold it back • not being able to urinate • weak or interrupted urine flow • painful or burning urination • blood in the urine • difficulty ...

LUNG Josephine Fleming set a world record as the first lung cancer patient to survive five years after starting gene therapy. A life-long resident of Denton, Texas, Fleming enjoys her eight grandchildren, going places with friends, and making tamales, pralines and peanut brittle. Just the Facts Lung Cancer Smoking is responsible for 87 percent of all lung cancer cases in the United States. Eliminating tobacco use is the key to reducing the impact of this disease. Symptoms Symptoms of lung cancer vary from person to person and may include: • a cough that will not go away and gets worse over time • constant chest pain, or arm and shoulder pain • coughing up blood • shortness of breath, wheezing or hoarseness • repeated episodes of pneumonia or bronchitis • swelling of the neck and face • loss of appetite and/or weight loss • fatigue ...

COLON Dr. Grace Butler, a former professor of higher education and colon cancer survivor, founded HOPE Through GRACE, Inc. She’s a cancer advocate who teaches people the importance of prevention and screening. Just the Facts Colorectal Cancer Your best chance for surviving colorectal cancer is detecting it early. When found early,there is nearly a 90 percent chance for cure. Symptoms There often are no symptoms of colorectal cancer in its early stages. Most colorectal cancers begin as a polyp, a small, non-cancerous growth on the colon wall that can grow larger and become cancerous. As polyps grow, they can bleed or obstruct the intestine. Symptoms include: • rectal bleeding • blood in the stool or toilet after a bowel movement • prolonged diarrhea or constipation • a change in the size or shape of your stool • abdominal pain ...

The Use of Preoperative Radiotherapy in the Management of Patients with Clinically Resectable Rectal Cancer Practice Guideline Report #2-13 A. Figueredo, L. Zuraw, R.K.S. Wong, O. Agboola, R.B. Rumble, V. Tandan, and members of the Gastrointestinal Cancer Disease Site Group. ORIGINAL GUIDELINE: December 12, 2002 MOST RECENT LITERATURE SEARCH: January 2004 NEW EVIDENCE ADDED TO GUIDELINE REPORT: January 2004 Based on the publication peer-review process and updating procedures, the Gastrointestinal Cancer Disease Site Group has modified this practice guideline report. The revised sections are labelled UPDATE. SUMMARY Guideline Questions Should patients with resectable rectal cancer receive preoperative radiotherapy to improve survival and prevent or delay local recurrence? Should preoperative radiotherapy replace the present common practice of postoperative ...

For more information call toll free: 1-800-ACS-2345 or on the Internet, http://www. cancer .org National Home Office: American Cancer Society, Inc., 1599 Clifton Road NE, Atlanta, GA 30329-4251, (404) 320-3333 National Media Office: 1180 Avenue of the Americas, New York, NY 10036, (212) 382-2169 ©1997, American Cancer Society, Inc. 97-300M-No. 5008.97 The American Cancer Society is the nationwide, community-based, voluntary health organization dedicated to eliminating cancer as a major health problem by preventing cancer , saving lives and diminishing suffering from cancer , through research, education, advocacy, and service. Page 2 S pecial S ection: RA CIAL AND ETHNI C P A T TER N S Estimated number of new cancer cases in 1997 by state, total: 1,382,400 (excluding Puerto ...

Use of Vinorelbine in Non-Small Cell Lung Cancer Practice Guideline Report # 7-5 ORIGINAL GUIDELINE: AUGUST 15, 1996 UPDATE: August 2001 This summary integrates the original practice guideline with the most current information (labeled NEW). SUMMARY Guideline Question Is there a role for the use of vinorelbine (Navelbine ® ) in the treatment of patients with non-small cell lung cancer (NSCLC)? Target Population These guidelines apply to adult patients with non-small cell lung cancer (NSCLC). Recommendations • Evidence from randomized controlled trials supports the use of vinorelbine as an option for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer . • The use of vinorelbine as a single agent, or in combination with cisplatin, depends on anticipated trade-offs between the expected symptomatic ...

Spring 2000 1 Early Detection of Breast Cancer in Counties Participating in the Illinois Breast and Cervical Cancer Program The Illinois Breast and Cervical Cancer Program (IBCCP) provides free or reduced cost mammograms, Pap tests, and other related screening and diagnostic services to income-eligible Illinois women. Funded through the U.S. Centers for Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program, it began as a demonstration program in 1995 in DuPage, Lake and Peoria counties. Illinois continued to receive federal funding to augment IBCCP in 1996 and 1997. In 1999, IBCCP was able to begin providing screening services to eligible women living in all 102 Illinois counties. The IBCCP targets women who are at or below 200 percent of the federal poverty guideline. Women eligible for breast cancer ...

1 Lesbian Family Denied Health Coverage for Terminal Cancer A Profile of Lisa Stewart i Lisa Stewart, a 33-year-old South Carolina native, lives with her partner of 10 years, Lynn, and their five-year old daughter, Emily. In March 2000 Lisa was diagnosed with breast cancer . Up until that point, life was “about as good as it could get for us,” says Lisa. They had a beautiful daughter, had just bought a second home and were able to travel during the summers. Unfortunately the cancer progressed to stage four or terminal cancer . In dealing with her illness, Lisa became painfully aware of the non-recognition of her relationship to Lynn and the family struggled through many different obstacles. Lisa was unable to keep her job as a real estate appraiser because of her cancer -related disability. Not only did she lose her income, but she also lost her health ...

14 The prevention of cancer is a major goal of public health programmes. Cancers may be prevented by avoiding expo- sure to known cancer -causing agents and lifestyle factors that increase cancer risk. However, even after expo- sure to a carcinogen has oc- curred, the multistep process of cancer development may be slowed, halted or reversed by a variety of strategies, thereby preventing progres- sion to clinically recognized disease. In 1996, IARC estab- lished a programme to evalu- ate cancer prevention strate- gies. This initiative aims to provide a scientific basis for national and international de- cisions on the implementation of cancer preventive strate- gies, and for assessing the as- sociated benefits and risks. The evaluations of the IARC working groups are scientific, qualitative judgements about the evidence ...

Estimated New Cancer Cases and Deaths by Sex for All Sites, US, 2004 * Estimated New Cases Estimated Deaths Both Sexes Male Female Both Sexes Male Female All sites 1,368,030 699,560 668,470 563,700 290,890 272,810 Oral cavity & pharynx 28,260 18,550 9,710 7,230 4,830 2,400 Tongue 7,320 4,860 2,460 1,700 1,100 600 Mouth 10,080 5,410 4,670 1,890 1,070 820 Pharynx 8,250 6,330 1,920 2,070 1,460 610 Other oral cavity 2,610 1,950 660 1,570 1,200 370 Digestive system 255,640 135,410 120,230 134,840 73,240 61,600 Esophagus 14,250 10,860 3,390 13,300 10,250 3,050 Stomach 22,710 13,640 9,070 11,780 6,900 4,880 ...

HADRON THERAPY FOR CANCER TREATMENT Seminar presented by Arlene Lennox at Fermilab on Nov 21, 2003 Page 2 CANCER STAGES LOCAL TUMOR LOCAL TUMOR REGIONAL METASTASIS REGIONAL METASTASIS SYSTEMIC DISEASE SYSTEMIC DISEASE Page 3 CANCER TREATMENT SURGERY RADIATION THERAPY CHEMOTHERAPY/IMMUNOTHERAPY Page 4 Photon radiation therapy is easily available Gantry rotates around patient. Therapy accelerators are manufactured by several vendors. Page 5 Hadron therapy is radiation therapy using strongly interacting particles •Neutrons •Protons •Pions •Ions (alphas, C, Ne) Reference: Petti and Lennox, Hadronic Radiotherapy, Ann. Rev. Nuclear & ...

THE Stop Cancer BEFORE IT STARTS CAMPAIGN How to Win the Losing War Against Cancer FEBRUARY 2003 Page 2 Page 3 THE STOP CANCER BEFORE IT STARTS CAMPAIGN How to Win the Losing War Against Cancer * Samuel S. Epstein, M.D. Chairman, Cancer Prevention Coalition (CPC) Professor emeritus, Environmental and Occupational Medicine 2121 West Taylor Street, Chicago, IL 60612; phone 312-996-2297; epstein@uic.edu www.preventcancer.com Copyright 2003 (ISBN 09715186-3-7) , The Cancer Prevention Coalition. All rights reserved. Sponsors Nicholas Ashford, Ph.D., J.D., Professor, Technology and Policy, Massachusetts Institute of Technology, Member, Governing Board (Massachusetts) Alliance for a Healthy Tomorrow, and CPC Board of Directors; Kenny Ausubel, ...

Health column 857 words BREAST CANCER UPDATE October is Breast Cancer Awareness month. In the United States, a woman’s lifetime risk of developing breast cancer is about 10 percent. More than half of these breast cancers will occur in women over age 65. But perhaps it is more important to understand the specific risk at a certain age. A woman aged 35, until age 55, without any other significant risk factors, has only a 2.5 percent potential risk of developing breast cancer over the next two decades. A woman who is 50 has a five percent chance of developing cancer over the next 25 years. An American woman who develops breast cancer has about a 3.5 percent chance of dying from breast cancer . Family, or genetic, risk factors appear to play a role in the development of breast cancer , however, in fact, a family history for breast cancer is infrequent. Although lung cancer has overtaken ...

© 2002 American Joint Committee on Cancer (AJCC) Staging Forms Chapter 3. Lip and Oral Cavity Chapter 4. Pharynx (Including Base of Tongue, Soft Palate, and Uvula) Chapter 5. Larynx Chapter 6. Nasal Cavity and Paranasal Sinuses Chapter 7. Major Salivary Glands (Parotid, Submandibular, and Sublingual) Chapter 8. Thyroid Chapter 9. Esophagus Chapter 10. Stomach Chapter 11. Small Intestine Chapter 12. Colon and Rectum Chapter 13. Anal Canal Cancer Staging Manual Staging Forms Sixth Edition Frederick L. Greene, M.D. David L. Page, M.D. Irvin D. Fleming, M.D. April G. Fritz, C.T.R., R.H.I.T. Charles M. Balch, M.D. Daniel G. Haller, M.D. Monica Morrow, M.D. Editors There are no Staging Forms for Chapters 1, 2 and 47 of the AJCC Cancer Staging Manual . Chapter 14. ...

Adjuvant Systemic Therapy for Node-negative Breast Cancer Practice Guideline Report #1-8 Members of the Breast Cancer Disease Site Group ORIGINAL GUIDELINE: November 12, 1998 NEW EVIDENCE ADDED TO GUIDELINE REPORT: February 2002 MOST RECENT LITERATURE SEARCH: May 1, 2003 The Breast Cancer Disease Site Group is rewriting this practice guideline report. The revised guideline report will incorporate all new evidence that has become available since the guideline was completed in 1998. The new evidence under review is identified in the update sections of the full report below. The current guideline recommendations remain in effect until the Breast Cancer Disease Site Group has completed their review of the new evidence. SUMMARY Guideline Question What is the role of systemic adjuvant therapy for women with node-negative breast cancer ? Target Population These recommendations ...

Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer Practice Guideline Report # 1-6 B.P.Findlay, C. Walker-Dilks, K. Pritchard, and members of the Breast Cancer Disease Site Group and the Systemic Treatment Disease Site Group. ORIGINAL GUIDELINE: March 11, 1997 MOST RECENT LITERATURE SEARCH: April 30, 2003 NEW EVIDENCE ADDED TO GUIDELINE REPORT: February 2002 New evidence found by update searches since completion of the original guideline is consistent with the original recommendations. SUMMARY Guideline Question What is the effectiveness of epirubicin, compared with doxorubicin, in patients with metastatic breast cancer ? Target Population Women with metastatic breast cancer . Recommendations Epirubicin, at doses equivalent to doxorubicin, has been shown to be equally efficacious and less toxic than doxorubicin. ...

The NHS Cancer Plan A plan for investment A plan for reform September 2000 ff f Page 2 Contents Foreword by the Secretary of State 3 Executive summary 5 Chapter One The challenge of cancer 16 Chapter Two Improving prevention 23 Chapter Three Improving screening 32 Chapter Four Improving cancer services in the community 43 Chapter Five Cutting waiting for diagnosis and treatment 48 Chapter Six Improving treatment 56 Chapter Seven Improving care 62 Chapter Eight Investing in staff 70 Chapter Nine Investing in facilities 83 Chapter Ten Investing in the future: research and genetics ...

Breast Cancer —Mammograms are still an effective tool Despite recent controversies over who should have mammograms, at what age, and how often, mammography (x-ray picture of the breast) remains the single most effective method for early detection of breast cancer . Early detection significantly decreases a woman’s risk of dying from breast cancer . What is cancer ? It is a group of diseases in which cells in the body become abnormal and divide without control. More cells are made than are needed and form a mass, or tumor . As the tumor continues to grow, it damages and grows into nearby tissues and organs. Finally, cells can break away and enter the blood stream or lymphatic system, spreading to distant places in the body. This is called metastasis. Breast cancer is a growth of abnormal, malignant cells in the breast. Most breast cancers occur in women, but about one percent of breast cancer occurs in men. ...

1 Colorectal Cancer Screening: An Era of Optimism March is Colorectal Cancer (CRC) Awareness Month which gives us a chance to think about this second most deadly of all human cancers in North America. Most colorectal cancers arise from benign polyps, small bumps in the colon lining. All studies show that as much as 30 percent of the population have one or more such polyps after the age of 50. It takes seven to ten years however for pre-cancerous polyps to transform into cancer , during which time there may be no warning signs or symptoms. It then takes another one to three years for the cancer to grow beyond the colon and spread to other organs. At this stage, the spreading cancer may become symptomatic with the presence of blood in the stool and/or pain from blockage of the bowel. By this time though, it is much more difficult to treat. It is best to find these benign polyps early when patients have the best ...